US2021283127A1PendingUtilityA1

Pharmaceutical compositions comprising poh derivatives

Assignee: NEONC TECH INCPriority: Aug 27, 2010Filed: May 6, 2021Published: Sep 16, 2021
Est. expiryAug 27, 2030(~4.1 yrs left)· nominal 20-yr term from priority
A61P 35/00A61K 47/54A61K 47/543C07D 231/12C07D 207/26A61K 31/045C07C 2601/16C07B 2200/05A61K 31/4015A61K 31/415A61K 47/542C07D 487/04A61P 25/00A61P 35/02A61K 31/4188A61N 5/10A61K 31/495A61K 45/06C07B 59/00A61K 9/0043C07C 33/14
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating a disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising octadeca-9, 12-dienoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (linoleoyl ester of POH) and at least one pharmaceutically acceptable carrier or diluent. 
     
     
         2 . The method of  claim 2 , wherein the pharmaceutical composition is administered before, during or after radiation treatment. 
     
     
         3 . The method of  claim 2 , further comprising administering to the mammal a chemotherapeutic agent. 
     
     
         4 . The method of  claim 2 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         5 . The method of  claim 2 , wherein the disease is cancer. 
     
     
         6 . The method of  claim 5 , wherein the cancer is selected from the group consisting of: lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; breast cancer; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia including acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma, neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system; and combinations thereof. 
     
     
         7 . A method for treating a disease in a mammal, comprising the step of delivering to the mammal pharmaceutical composition comprising hexadecanoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (palmitoyl ester of POH) having the chemical formula: 
       
         
           
           
               
               
           
         
         and at least one pharmaceutically acceptable carrier or diluent. 
       
     
     
         8 . The method of  claim 7 , further comprising delivering to the mammal a chemotherapeutic agent. 
     
     
         9 . The method of  claim 7 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         10 . The method of  claim 7 , wherein the disease is cancer. 
     
     
         11 . The method of  claim 10 , wherein the cancer is selected from the group consisting of: lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; breast cancer; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia including acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma, neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system; and combinations thereof.

Join the waitlist — get patent alerts

Track US2021283127A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.